However, growing evidence suggests that TP53 concurrently contributes to the regulation of tumor immune response [2,3,4,5,6]; a significant activation of inflammatory and innate immune pathways in CRC caused by TP53 mutation have already been found [7]. Here, TP53 is linked to neoplasm.